TextbookHaematologyDisseminated Intravascular Coagulation

Disseminated Intravascular Coagulation

Life-threatening consumptive coagulopathy with simultaneous widespread thrombosis and haemorrhage, always secondary to an underlying condition such as sepsis or malignancy.

Key Facts

DIC is always secondary to an underlying condition – most commonly sepsis, trauma, obstetric emergencies, and malignancy Characterised by simultaneous activation of coagulation and fibrinolysis → consumption of clotting factors and platelets Key lab findings: prolonged PT/APTT, low fibrinogen (<1.5 g/L), raised D-dimer, thrombocytopenia, schistocytes on film ISTH DIC scoring system: platelets, D-dimer, fibrinogen, PT prolongation – score ≥5 indicates overt DIC Management is primarily treating the underlying cause Cryoprecipitate (target fibrinogen >1.5 g/L), FFP (if PT ratio >1.5), platelets (if <50 and bleeding or <30 × 10⁹/L) Mortality depends on underlying cause but is 30-50% overall in overt DIC

Overview

Key Facts

DIC is a complex, acquired coagulopathy characterised by systemic intravascular activation of coagulation, leading to fibrin deposition, microvascular thrombosis, and consumption of clotting factors and platelets, resulting in simultaneous thrombosis and haemorrhage.

Epidemiology

  • Occurs in ~1% of hospitalised patients (higher in ICU)
  • Most common precipitant: sepsis (30-50% of cases)
  • Affects all ages, no sex predominance

Aetiology

  • Sepsis/infection: Gram-negative (endotoxin) > Gram-positive, meningococcal, malaria
  • Trauma/surgery: major trauma, burns, head injury, fat embolism
  • Obstetric: amniotic fluid embolism, placental abruption, HELLP, eclampsia, septic abortion
  • Malignancy: acute promyelocytic leukaemia (APL, M3), pancreatic cancer, mucin-secreting adenocarcinomas
  • Vascular: aortic aneurysm, giant haemangioma (Kasabach-Merritt)
  • Other: transfusion reactions, envenomation, liver failure

Pathophysiology

  • Underlying trigger causes massive tissue factor release → activation of extrinsic coagulation cascade
  • Widespread thrombin generation → fibrin deposition in microcirculation → microthrombi → organ damage
  • Consumption of clotting factors (II, V, VIII, fibrinogen) and platelets → coagulopathy and bleeding
  • Secondary fibrinolysis (plasmin activation) → elevated D-dimers and FDPs
  • RBCs sheared through fibrin strands → microangiopathic haemolytic anaemia (schistocytes)
  • Can be acute (fulminant, bleeding dominant – sepsis, trauma) or chronic (thrombosis dominant – malignancy)

Clinical Presentation

Acute DIC (Bleeding Predominant)

  • Bleeding from multiple sites: venepuncture sites, surgical wounds, catheters
  • Petechiae, purpura, ecchymoses
  • Mucosal bleeding: epistaxis, gingival bleeding, haematuria, GI bleeding
  • Organ dysfunction: renal failure, ARDS, hepatic dysfunction
  • Shock: from blood loss and underlying condition

Chronic DIC (Thrombosis Predominant)

  • Venous thromboembolism: DVT, PE
  • Arterial thrombosis: digital gangrene, stroke
  • Trousseau syndrome: migratory thrombophlebitis (associated with malignancy)
  • Purpura fulminans: severe skin necrosis with microvascular thrombosis

Red Flags

  • Purpura fulminans (meningococcal sepsis) → emergency resuscitation
  • Oozing from all puncture sites → suspect DIC in critically ill patient
  • Acute promyelocytic leukaemia → DIC at presentation requiring immediate ATRA and factor replacement
  • Massive obstetric haemorrhage → DIC likely, activate major haemorrhage protocol

Differential Diagnosis

DiagnosisKey FeaturesInvestigation
TTP/HUSNormal coagulation, severe MAHAADAMTS13, coagulation normal
Severe liver diseaseCoagulopathy but often no MAHALFTs, no schistocytes
Heparin-induced thrombocytopeniaPlatelet drop + thrombosis, heparin exposure4T score, anti-PF4
Primary fibrinolysisLow fibrinogen but normal/mildly abnormal PTEuglobulin clot lysis time
Massive transfusion coagulopathyDilutional coagulopathy, trauma settingClinical context
Vitamin K deficiencyProlonged PT, normal platelets and fibrinogenResponse to vitamin K

Diagnosis / Investigation

Bedside

  • Clinical assessment: bleeding from multiple sites, signs of underlying cause
  • Observations: signs of shock, organ dysfunction

Bloods

  • Coagulation screen: prolonged PT and APTT
  • Fibrinogen: low (<1.5 g/L, often <1.0 g/L in severe DIC)
  • D-dimer: markedly elevated (most sensitive but least specific)
  • FBC: thrombocytopenia (or rapidly falling platelet count)
  • Blood film: schistocytes (fragmented RBCs)
  • FDP (fibrin degradation products): elevated
  • LDH: elevated (haemolysis and tissue damage)
  • Haptoglobin: low (haemolysis)
  • Thrombin time: prolonged

Imaging

  • As directed by underlying cause (CT for trauma, obstetric assessment)

Special Tests

  • ISTH DIC scoring system (repeated serially to monitor trend)
  • Thromboelastography (TEG/ROTEM): point-of-care assessment of coagulation status
  • Serial coagulation monitoring: every 4-6 hours in acute DIC

Management

Non-pharmacological

  • Treat the underlying cause – this is the MOST IMPORTANT intervention
    • Sepsis: antibiotics, source control
    • Obstetric: delivery of placenta/fetus
    • APL: all-trans retinoic acid (ATRA)
  • Activate major haemorrhage protocol if severe bleeding

Pharmacological

Replacement therapy (for bleeding or prior to invasive procedures):

  • Cryoprecipitate: 2 pools (10 units) – target fibrinogen >1.5 g/L (>2.0 g/L in obstetric DIC)
  • Fresh frozen plasma (FFP): 15-20 mL/kg – if PT ratio >1.5 and bleeding
  • Platelet transfusion: target >50 × 10⁹/L if bleeding; >30 if not bleeding; >100 if CNS bleeding
  • Tranexamic acid 1g IV: consider as adjunct for hyperfibrinolysis (CRASH-2 trial supports in trauma)

Anticoagulation (chronic/thrombotic DIC):

  • Unfractionated heparin infusion in select cases (thrombosis-dominant DIC, e.g., malignancy)
  • Low-dose LMWH prophylaxis in non-bleeding patients

Specific treatments:

  • All-trans retinoic acid (ATRA) for APL-associated DIC
  • Protein C concentrate – historically studied but not widely used

Referral Criteria

  • All patients with DIC → critical care/haematology
  • Obstetric DIC → obstetric emergency team
  • Haematological malignancy with DIC → specialist haematology centre

Prognosis

  • Overall mortality: 30-50% in overt DIC (depends on underlying cause)
  • Sepsis-associated DIC: mortality 40-60%
  • Obstetric DIC: generally good prognosis if underlying cause treated promptly (mortality <5%)
  • Malignancy-associated DIC: prognosis linked to underlying cancer
  • APL with DIC: good prognosis with ATRA treatment (cure rate >85%)
  • Serial DIC score monitoring: improving score predicts better outcome

Other Relevant Information

ISTH DIC Scoring System

ParameterScore 0Score 1Score 2Score 3
Platelets (×10⁹/L)>10050-100<50-
D-dimerNormalModerate ↑Strong ↑-
Fibrinogen (g/L)>1.0-≤1.0-
PT prolongation (s)<33-6>6-

Score ≥5 = Overt DIC; <5 = Non-overt (repeat in 24h)

Acute vs Chronic DIC

FeatureAcute DICChronic DIC
OnsetHoursWeeks-months
Dominant featureBleedingThrombosis
CauseSepsis, trauma, obstetricMalignancy
FibrinogenVery lowNormal/raised
PlateletsVery lowLow-normal